Welcome to PrEP Watch, a clearinghouse for information on pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP Watch includes information on data, additional research, cost, access and advocacy efforts in the United States and across the globe.


Resources to Understand PrEP

PrEP is a new and emerging HIV prevention intervention in which HIV-negative individuals take an antiretroviral (ARV) to reduce their individual risk of acquiring HIV. More here.

PrEP Data to-Date

A number of large-scale trials from a range of populations and in different areas of the world have generated data showing that daily oral TDF/FTC (Truvada) is safe and effective to reduce the risk of HIV infection for HIV-negative people. More here.

Guidance

Guidelines for prescribing and using PrEP are available from a range of groups, including state health departments in the US, the US Centers for Disease Control (CDC) and national-level clinician groups as well as guidelines on international demonstration projects from the World Health Organization. More here.

Implementing PrEP in the “Real World”

Depending on location, communities are at varying stages of implementing PrEP. In the US the Food and Drug Administration (FDA) has approved daily Truvada for HIV prevention, and some communities in the US are exploring how it might best be delivered. Outside of the US, Truvada as PrEP is not approved by local regulators and in most cases remains inaccessible outside of research studies. Country-specific information is being collected. More here.

Cost, Access and Using PrEP

There is a growing body of information on how to access PrEP and how its cost can be covered in the US. There is limited access elsewhere outside of clinical trials or demonstration projects. More here.

Ongoing research

At the same time, additional clinical trial research is ongoing to test new regimens—twice-weekly, for example—and different ARVs, like maraviroc. More here.

Local Advocacy

Advocacy efforts supporting both the PrEP research pipeline and PrEP access for populations most in need are active in areas around the world. More here


Other HIV Prevention Research

PrEP is just one element of the ARV-based and wider biomedical HIV prevention agenda, which include a range of proven approaches and others under study. More here.

Quick Links

What’s new

Why I Started Supporting PrEP

“While not a panacea, I have embraced PrEP as a viable public health intervention and one of few options we have that could help us achieve an AIDS-free generation.”

The Latest Webinars

Audio and slides are available from two recent PrEP webinars; click here.

Getting PrEP A Very Bumpy Ride

The blog My PrEP Experience has an illuminating story about one man’s difficulty accessing PrEP.

New Video: PrEParing for HIV

The video from UCTV explains PrEP science and discusses ongoing demonstration projects in California.


Updates from the Conference on Retroviruses and Opportunistic Infections

Lancet article: PrEP will have greatest effect if targeted to highest-risk groups

Read the secondary analysis of the iPrEx trial here.

Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco

Read the paper here.

Long-acting injectable shows promise

PrEP candidate GSK744 protects Monkeys in new study. Read more here.